Table 2.
MRI results in the vitamin D-and placebo-treated active subgroup patients.
| Vitamin D | Placebo | P value | ||||
|---|---|---|---|---|---|---|
| T2 BOD (mm3), median (SE) |
Baseline | n = 15 | 4391 (2305) | n = 15 | 9930 (2375) | 0.105 |
| Change from baseline | n = 13 | 104 (240) | n = 14 | 570 (3259) | ||
| Number of T1-enhancing lesions, mean (SD) |
Baseline | n = 15 | 1.5 (3.6) | n = 15 | 1.5 (2.9) | |
| Month 12 | n = 13 | 0.1 (0.3) | n = 14 | 1.5 (5.0) | 0.027∗ | |
| Patients with T1-enhancing lesions (n,%) | Baseline | n = 15 | 6 (40%) | n = 15 | 6 (40%) | |
| Month 12 | n = 13 | 1 (8%) | n = 14 | 3 (21%) | ||
| Number of new or enlarging T2/PD lesions, median (SD) | Month 12 | n = 13 | 0.61 (1.26) | n = 14 | 1.85 (2.44) | 0.132 |
| Patients with new or enlarging lesions on T2/PD, mean (SD) | Month 12 | n = 13 | 3 (23%) | n = 13 | 8 (57%) | NS |
| MRI activity (n,%) | Baseline | n = 15 | 6 (40%) | n = 15 | 6 (40%) | 0.080 |
| Month 12 | n = 13 | 3 (23%) | n = 14 | 8 (57%) |
BOD: burden of disease; MRI activity: Gadolinium-enhancing T1 lesions or new/enlarging T2 lesions; n: number of patients. ∗Indicates statistically significant. NS: not significant.